German HTA likely to toughen path for orphan drugs, warns industry association
This article was originally published in SRA
Companies developing orphan drugs should prepare for changes to Germany's early benefit assessment system that could make staying on the market with a reasonable price tougher, warns the European Confederation of Pharmaceutical Entrepreneurs (Eucope)1.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.